## Check for updates

## OPEN ACCESS

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

\*CORRESPONDENCE Frontiers Production Office, production.office@frontiersin.org

#### SPECIALTY SECTION

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

RECEIVED 13 December 2022 ACCEPTED 13 December 2022 PUBLISHED 09 January 2023

#### CITATION

Frontiers Production Office (2023), Erratum: Advances in RIPK1 kinase inhibitors. *Front. Pharmacol.* 13:1123234. doi: 10.3389/fphar.2022.1123234

#### COPYRIGHT

© 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Erratum: Advances in RIPK1 kinase inhibitors

# Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

### KEYWORDS

inhibitor, receptor interacting protein 1 (RIP1), programmed necrosis, necrosis, RIP1 (RIPK1)

## An Erratum on

Advances in RIPK1 kinase inhibitors

by Chen L, Zhang X, Ou Y, Liu M, Yu D, Song Z, Niu L, Zhang L and Shi J (2022). Front. Pharmacol. 13:976435. doi: 10.3389/fphar.2022.976435

Due to a production error, the list of affiliations used for the authors was incorrect. The correct affiliations list is shown below.

Lu Chen<sup>1,2,†</sup>, Xiaoqin Zhang<sup>3,†</sup>, Yaqing Ou<sup>4,†</sup>, Maoyu Liu<sup>1,2,†</sup>, Dongke Yu<sup>1,2</sup>, Zhiheng Song<sup>5</sup>, Lihong Niu<sup>6,\*</sup>, Lijuan Zhang<sup>1,2,\*</sup> and Jianyou Shi<sup>1,2,\*</sup>

<sup>1</sup>Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

<sup>2</sup>Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

<sup>3</sup>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China

<sup>4</sup>Department of Pharmacy, The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, Sichuan, China

<sup>5</sup>Suzhou University of Science and Technology, Suzhou, Jiangsu, China, 6 Institute of Laboratory Animal Sciences, Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

The publisher apologizes for this mistake. The original version of this article has been updated.